The advantage of early detection of pre-eclampsia is the possibility to initiate low-dose aspirin therapy before Week 16 of amenorrhoea and/or to implement close monitoring of the pregnancy. This screening, during the 1st trimester of pregnancy, combines PAPP-A and PIGF assays (Delfia Xpress™ system, Perkin Elmer). The risk of PE is calculated by the software (Predictor™) using the levels of PAPP-A and PIGF, biophysical measurements (blood pressure, uterine artery Doppler scan), demographic information on the patient (BMI, geographic origin, smoker/non-smoker, etc.), her medical history (number of prior viable pregnancies, PE, and high blood pressure), and the ongoing pregnancy (gestational age, the date of the ultrasound, and the CRL).
Pre-eclampsia predictive test
This test is for symptomatic patients beyond Week 24 of amenorrhea. The use of the sFlt-1/PlGF ratio allows the occurrence of pre-eclampsia (PE) to be predicted within 1 to 4 weeks. This ratio can help the doctor decide whether to keep the patient at home to or bring them in to the hospital, as well as adjust treatment and anticipate foetal-maternal complications.
The placental growth factor (PIGF) and sFlt-1 antiangiogenic factor are biomarkers that are closely linked to PE. An imbalance in the concentration of these two markers occurs several weeks before the first clinical signs of pre-eclampsia. As such, an increased sFlt-1/PlGF ratio is associated with a risk of pre-eclampsia.
Our biologists are members of the Groupe de Biologie Spécialisée de la Société Française de Médecine Nucléaire (Specialised Biology Group of the French Society of Nuclear Medicine), SFBC (Société Française de Biologie Clinique; French Society of Clinical Biology), and ELAS (European Ligand Assays Society).